Scholarlink

<p>To evaluate the prognostic role of patient-reported outcomes (PROs) in nonmetastatic breast cancer, we conducted secondary analysis of 2763 women in A011502, a randomized trial of adjuvant aspirin vs. placebo. High stress (Perceived Stress Scale) was associated with worse invasive disease-free survival (iDFS) (adjusted hazard ratio (aHR) 2.22) and distant recurrence-free survival (DRFS) (aHR 2.3). Moderate/severe pain (Brief Pain Inventory) predicted worse iDFS (aHR 1.67), DRFS (aHR 1.83), distant recurrence-free interval (aHR 1.53) and overall survival (aHR 2.21). PROs may enhance risk stratification in survivorship care. Trial Registration: ClinicalTrials.gov: NCT02927249.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of patient-reported stress and pain with survival in nonmetastatic breast cancer: secondary analysis of Alliance A011502

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月5日

查看全文
  • Shipra Gandhi,
  • Karla V. Ballman,
  • Sarah K. Reed,
  • Michelle D. Holmes,
  • Kala Visvanathan,
  • Banu Symington,
  • Anna Weiss,
  • Amylou C. Dueck,
  • Eric P. Winer,
  • Lisa A. Carey,
  • Ann H. Partridge,
  • Wendy Y. Chen

摘要

To evaluate the prognostic role of patient-reported outcomes (PROs) in nonmetastatic breast cancer, we conducted secondary analysis of 2763 women in A011502, a randomized trial of adjuvant aspirin vs. placebo. High stress (Perceived Stress Scale) was associated with worse invasive disease-free survival (iDFS) (adjusted hazard ratio (aHR) 2.22) and distant recurrence-free survival (DRFS) (aHR 2.3). Moderate/severe pain (Brief Pain Inventory) predicted worse iDFS (aHR 1.67), DRFS (aHR 1.83), distant recurrence-free interval (aHR 1.53) and overall survival (aHR 2.21). PROs may enhance risk stratification in survivorship care. Trial Registration: ClinicalTrials.gov: NCT02927249.